Evidence map›Paper›PMID 40661925›Full record

ArticleClinical kidney journal2025

Terlipressin for sinusoidal obstruction syndrome-associated acute kidney injury: a novel application.

Callie J Meath, Bindu Simon, Rohtesh S Mehta, Partow Kebriaei, Jamie S Lin

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Callie J MeathDepartment of Internal Medicine-Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Bindu SimonSection of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rohtesh S MehtaDepartment of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Partow KebriaeiDepartment of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jamie S LinSection of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-7073-9658

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of hematopoietic cell transplantation that can lead to multiorgan failure, including acute kidney injury (AKI) due to hepatorenal syndrome (HRS)-like physiology. Current supportive measures often fail in preserving renal function, and dialysis is associated with high mortality risk. Terlipressin, a vasopressin analog approved for HRS in cirrhosis, has not been previously described for SOS-AKI. We report the first detailed case of terlipressin improving renal function, restoring diuretic responsiveness, and preventing dialysis in a patient with SOS, highlighting its potential as a therapeutic option for SOS-related renal failure.

Indexed as

acute kidney injuryhematopoietic cell transplanthepatorenal syndromesinusoidal obstructive syndrometerlipressin

Identifiers

PMID40661925
PMCPMC12259277

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.